3 cheap FTSE 100 dividend shares I’d buy now

These three dividend-paying FTSE 100 shares are valued attractively and have the potential to move higher, says Edward Sheldon, CFA.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Many FTSE 100 shares have performed well over the last few months. It’s fair to say that there’s a lot less value on offer today than there was in late March when the FTSE 100 was trading below 5,000 points.

That being said, there are still plenty of FTSE 100 shares that trade at very attractive valuations at present. Here’s a look at three cheap dividend-paying FTSE 100 stocks I’d be happy to buy today.

This FTSE 100 stock looks undervalued

The first cheap FTSE 100 stock I want to highlight is financial services giant Legal & General Group (LSE: LGEN). It currently trades on a forward-looking P/E ratio of just 7.4. At that valuation, I think the stock is significantly undervalued.

Earlier this month, analysts at Bank of America (BofA) Global Research upgraded LGEN to buy from neutral. They slapped a price target of 265p on the stock – 22% higher than the share price today.

BofA’s analysts also commented on LGEN’s bumper dividend yield, which currently stands at over 8%. “We think this is a particularly appealing proposition in a market starved of yield. Further, we think that the regulatory risk to the dividend is low,” they wrote to clients.

I fully agree with the BofA analysts’ view on Legal & General shares. I think the dividend yield here is very attractive. I’d buy this FTSE 100 share today.

Great buying opportunity

Another dividend-paying FTSE 100 share I’d be happy to buy today is Hikma Pharmaceuticals (LSE: HIK). It’s a fast-growing healthcare company that manufactures branded and non-branded generic medicines.

Hikma’s share price has fallen recently, despite the fact that the company issued a very encouraging trading update in April. The reason the shares have dropped? A major shareholder has sold a large amount of stock.

Personally, I think this share price weakness is a great buying opportunity. And I’m not the only one who sees an opportunity right now. Earlier this month, analysts at Morgan Stanley upgraded the stock to ‘overweight’ from ‘equal-weight’ and raised their price target from 2,200p to 2,600p. That price target is around 20% higher than the current share price.

Hikma shares currently trade on a forward-looking P/E ratio of 17.4. I think that’s quite cheap. The dividend yield on offer is about 1.6%.

A FTSE share with a 5% dividend yield

Finally, I also like the look of GlaxoSmithKline (LSE:GSK) right now.

I think GSK is a great stock to own in the current environment. For a start, I like the fact that the FTSE 100 company is one of the largest vaccine manufacturers in the world. This means it could play a key role in the fight against Covid-19. Just recently, the company advised that it was making a $163m investment in German biotech CureVac, to work together on a vaccine for the coronavirus.

Another thing I like about GSK is that it owns a whole portfolio of consumer healthcare brands that includes the likes of Voltaren, Panadol, and Fenbid. These kinds of trusted brands are attractive assets as they tend to generate consistent cash flows. That means GSK has defensive qualities.

GSK shares currently trade on a forward-looking P/E ratio of about 13.4. That’s an attractive valuation, in my view. The stock also offers a prospective dividend yield of about 5.1%. I’d be happy to buy this FTSE 100 champion today.

Edward Sheldon owns shares in Legal & General Group and GlaxosmithKline. The Motley Fool UK has recommended GlaxoSmithKline and Hikma Pharmaceuticals. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Man hanging in the balance over a log at seaside in Scotland
Investing Articles

Are Barclays shares trading at a 50% discount?

On some metrics, Barclays shares could be looked at as half price. Is this a fair way to look at…

Read more »

Landlady greets regular at real ale pub
Investing Articles

After toppling 11%, are Wetherspoons shares too cheap to miss?

Wetherspoons shares are sinking after a disappointing trading update on Friday (20 March). Is the FTSE 250 firm now a…

Read more »

The flag of the United States of America flying in front of the Capitol building
Investing Articles

2 S&P 500 tech titans to consider for a Stocks and Shares ISA 

Our writer sees a few blue chips from the S&P 500 that are worth considering for a Stocks and Shares…

Read more »

Group of young friends toasting each other with beers in a pub
Investing Articles

JD Wetherspoon’s share price takes a sobering 10% dip!

JD Wetherspoon's share price tanked today (20 March), after the pub chain published its latest results. James Beard reckons it’s…

Read more »

Portrait of elderly man wearing white denim shirt and glasses looking up with hand on chin. Thoughtful senior entrepreneur, studio shot against grey background.
Investing Articles

I asked ChatGPT when the Taylor Wimpey shares turnaround is coming and it said…

Taylor Wimpey shares have fallen a long way from all-time highs. Might a stunning recovery be on the cards for…

Read more »

Long-term vs short-term investing concept on a staircase
Investing Articles

My JD Wetherspoon shares just fell 12% in a day! Here’s what I’m doing

JD Wetherspoon shares just fell sharply on news of lower profits. But are these short-term challenges or is there a…

Read more »

Santa Clara offices of NVIDIA
Investing Articles

Nvidia stock price forecast: could we see $300 in 2026?

Nvidia stock has paused for breath recently. However, Wall Street analysts seem to believe that it’s just a matter of…

Read more »

Older Man Reading From Tablet
Investing Articles

How to shelter a SIPP from a nasty stock market crash

Edward Sheldon outlines some simple strategies that could help SIPP investors protect their wealth against an equity market meltdown.

Read more »